These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 2056770)

  • 61. Characterization of genomic BCR-ABL breakpoints in chronic myeloid leukaemia by PCR.
    Zhang JG; Goldman JM; Cross NC
    Br J Haematol; 1995 May; 90(1):138-46. PubMed ID: 7786776
    [TBL] [Abstract][Full Text] [Related]  

  • 62. BCR-ABL transcript with an e19a2 (c3a2) junction in classical chronic myeloid leukemia.
    Wilson G; Frost L; Goodeve A; Vandenberghe E; Peake I; Reilly J
    Blood; 1997 Apr; 89(8):3064. PubMed ID: 9108430
    [No Abstract]   [Full Text] [Related]  

  • 63. Relationship between the type of BCR-ABL rearrangement and bone marrow histopathological features in chronic myeloid leukemia.
    Colleoni GW; Silva MR; Silva RS; Costa FF; Kerbauy J; Saad ST
    Acta Oncol; 1997; 36(3):313-5. PubMed ID: 9208903
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Induction of BCR-ABL fusion genes by in vitro X-irradiation.
    Ito T; Seyama T; Mizuno T; Hayashi T; Iwamoto KS; Dohi K; Nakamura N; Akiyama M
    Jpn J Cancer Res; 1993 Feb; 84(2):105-9. PubMed ID: 8463127
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Near-hexaploid Ph-positive acute myeloid leukemia with major-BCR/ABL transcript.
    Iwama H; Ohyashiki K; Ohyashiki JH; Shimamoto T; Fujimura T; Kawakubo K; Kuriyama Y; Kodama A; Toyama K
    Cancer Genet Cytogenet; 1996 Jan; 86(1):61-4. PubMed ID: 8616789
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A polymorphism in exon b2 of the major breakpoint cluster region (M-bcr) identified in chronic myeloid leukaemia patients.
    Meissner RV; Dias PM; Covas DT; Job F; Leite M; Nardi NB
    Br J Haematol; 1998 Oct; 103(1):224-6. PubMed ID: 9792313
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Comprehensive characterization of a novel intronic pseudo-exon inserted within an e14/a2 BCR-ABL rearrangement in a patient with chronic myeloid leukemia.
    Sorel N; Mayeur-Rousse C; Deverrière S; Roy L; Brottier-Mancini E; Guilhot F; Turhan AG; Chomel JC
    J Mol Diagn; 2010 Jul; 12(4):520-4. PubMed ID: 20508029
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Heterogenous expression of bcr-abl fusion mRNA in a patient with Philadelphia-chromosome-positive acute lymphoblastic leukaemia.
    Inokuchi K; Futaki M; Hanawa H; Tanosaki S; Yamaguchi H; Iwakiri R; Nomura T; Dan K
    Br J Haematol; 1997 Jun; 97(4):837-40. PubMed ID: 9217185
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A novel acute lymphoid leukaemia type BCR/ABL transcript in chronic myelogenous leukaemia.
    Okamoto K; Karasawa M; Sakai H; Ogura H; Morita K; Naruse T
    Br J Haematol; 1997 Mar; 96(3):611-3. PubMed ID: 9054670
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Does the site of the breakpoint on chromosome 22 influence the duration of the chronic phase in chronic myeloid leukemia?
    Birnie GD; Mills KI; Benn P
    Leukemia; 1989 Aug; 3(8):545-7. PubMed ID: 2747287
    [No Abstract]   [Full Text] [Related]  

  • 71. Influence of M-BCR breakpoint sites on the duration of chronic phase in 100 patients with chronic myelocytic leukemia.
    Tanaka K; Hashimoto T; Oguma N; Dohy H; Kamada N
    Cancer Genet Cytogenet; 1993 Oct; 70(1):39-47. PubMed ID: 8221611
    [TBL] [Abstract][Full Text] [Related]  

  • 72. B3/A3 rearrangement in a patient with chronic myeloid leukemia.
    Paz-Y-Miño C; Arévalo M; Leone PE
    Leuk Lymphoma; 2003 Feb; 44(2):375-6. PubMed ID: 12688363
    [TBL] [Abstract][Full Text] [Related]  

  • 73. bcr-abl hybrid messenger RNA in a patient with Philadelphia-negative essential thrombocythemia.
    Hashino S; Imamura M; Kobayashi S; Kunieda Y; Kobayashi H
    Acta Haematol; 1995; 94(1):52-4. PubMed ID: 7544525
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Long-term culture and molecular biological studies highlight differences in relative BCR-ABL expression levels in the peripheral blood and bone marrow of a patient with chronic granulocytic leukaemia.
    Smith MA; Mills KI; Smith JG
    Br J Haematol; 1994 Oct; 88(2):406-8. PubMed ID: 7803292
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The relationship between the location of the breakpoint within the M-bcr and clinical parameters.
    Mills KI
    Leuk Lymphoma; 1993; 11 Suppl 1():73-9. PubMed ID: 8251922
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Reply to Haas: Are ABL and BCR imprinted? (Leukemia 1995; 9: 740-743).
    Melo JV; Goldman JM
    Leukemia; 1995 Aug; 9(8):1407-8. PubMed ID: 7643632
    [No Abstract]   [Full Text] [Related]  

  • 77. Development of chronic myelogenous leukemia in a case of chronic lymphocytic leukemia with Tp53 gene deletion.
    Gupta A; Parihar M; Yadav AK; Chakrapani A
    J Postgrad Med; 2015; 61(2):137-8. PubMed ID: 25766353
    [No Abstract]   [Full Text] [Related]  

  • 78. Relationship of the type of bcr-abl hybrid mRNA to clinical course and transforming activity in Philadelphia-positive chronic myelogenous leukemia.
    Futaki M; Inokuchi K; Matsuoka H; Miyake K; Dan K; Nomura T
    Leuk Res; 1992 Nov; 16(11):1071-5. PubMed ID: 1434743
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The position of the M-BCR breakpoint does not predict the duration of chronic phase or survival in chronic myeloid leukemia.
    Jaubert J; Martiat P; Dowding C; Ifrah N; Goldman JM
    Br J Haematol; 1990 Jan; 74(1):30-5. PubMed ID: 2310695
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Deletion of chromosome 22 without bcr rearrangement and without juxtaposition of c-abl in a case of acute myeloid leukemia.
    Xiao H; Baer MR; Block AW; Sait SN; Kakati S
    Cancer Genet Cytogenet; 1993 Jun; 67(2):141-4. PubMed ID: 8330271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.